Stocks · News reference
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged
Filed: 2026-10-08 AccNo: 0001193125-26-418065 Size: 696 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take regular weekly injections or daily pills. FibroBiologics is developing a different approach.The patent application